IN PREGNANT PATIENTS with Hodgkin's disease it is occasionally necessary to use various chemotherapeutic agents and to accept the possible risk of a teratogenic effect on the fetus. In most cases, however, potentially teratogenic agents have failed to produce deleterious effects on the human fetus when administered during and after the first trimester of pregnancy.1,2 In a few instances in humans, alkylating agents given during the first trimester of pregnancy have been associated with fetal anomalies.2,3
As more and more cases of pregnant patients with Hodgkin's disease who have received chemotherapy during pregnancy become known, the risk of such treatment may be diminished merely by the weight of empirical evidence against any serious effect on the fetus. With this in mind Sokol and Lessmann,1 Shirkey,4 and Lacher5 have stressed the equal importance of reporting normal data as well as anomalies.
The following report illustrates the
Mortimer J. Lacher, William Geller. Cyclophosphamide and Vinblastine Sulfate in Hodgkin's Disease During Pregnancy. JAMA. 1966;195(6):486–488. doi:10.1001/jama.1966.03100060126040